In the 2016 OPPS, did CMS authorize add-on payments for any other drugs than the one you mentioned last week—bilatumonmab?
The Centers for Medicare & Medicaid Services (CMS) did not authorize fiscal year 2016 add-on payments for isavuconazonium sulfate, a drug that the Food & Drug Administration (FDA) approved last March for the treatment of invasive fungal infections.
In addition, CMS discontinued add-on payments for glucarpidase but retained the payments for Kcentra prothrombin complex concentrate. The FY 2016 maximum add-on payment for Kcentra is $1,587.50 per case. Both biologics were eligible for the payments during FY 2015.